Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan

被引:172
|
作者
Miyakawa, Shuichi [1 ]
Ishihara, Shin [1 ]
Horiguchi, Akihiko [1 ]
Takada, Tadahiro [2 ]
Miyazaki, Masaru [3 ]
Nagakawa, Takukazu [4 ]
机构
[1] Fujita Hlth Univ, Dept Biliary & Pancreat Surg, Toyoake, Aichi 4701192, Japan
[2] Teikyo Univ, Dept Surg, Tokyo 173, Japan
[3] Grad Sch Med, Dept Gen Surg, Chiba, Japan
[4] Fukuno Hosp, Nanto, Toyama, Japan
来源
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY | 2009年 / 16卷 / 01期
关键词
Biliary tract cancer; Statistics registry; 5-year survival; Stage of disease; Lymph node metastasis; LONG-TERM SURVIVAL; AMPULLARY CARCINOMAS; GALLBLADDER CANCER; SURGERY; CHOLANGIOCARCINOMA; GUIDELINES; MANAGEMENT; RECURRENCE; VATER; EXPERIENCE;
D O I
10.1007/s00534-008-0015-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The results from the Japanese Biliary Tract Cancer Statistics Registry from 1988 to 1998 were reported in 2002. In the present study, we report here selectively summarized data as an overview of the 2006 follow-up survey of the registered cases from 1998 to 2004 for information bearing on problems with the treatment of cancer of the biliary tract. A total of 5,584 patients were registered from 1998 to 2004. The site of cancer was the bile duct in 2,732 patients, the gallbladder in 2,067, and the papilla of Vater in 785. Those cases were analyzed with regard to patient survival according to the extent of tumor invasion (pT), the extent of lymph node metastasis (pN) and the stage. The five-year survival rate after surgical resection was 33.1% for bile duct cancer, 41.6% for gallbladder cancer, and 52.8% for cancer of the papilla of Vater. For hilar or superior bile duct cancer, the 5-year survival rate was lower with an increase in the pT, pN and f stage, except pT3 vs. pT4, pN1 vs. pN2 and stage III vs. stage IVa. For middle or distal bile duct cancer, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT2 vs. pT3, pN2 vs. pN3, stage II vs. stage III and stage III vs. stage IVa. For gallbladder cancer, the 5-year survival rate was lower with increase in pT, pN and f stage. For cancer of the papilla of Vater, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT1 vs. pT2, pN1 vs. pN2, and stage III vs. stage IVa. In the present study, the outcomes of surgical treatment were better than that of the previous report from Japan and foreign countries. The pT, pN and stage of gallbladder cancer are well defined. However, there were no significant differences in some groups of those of bile duct cancer and cancer of the papilla of Vater.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [31] The evolution of biliary tract cancer: introducing a special focus issue from Immunotherapy
    Coyle, Lauren
    Rizzo, Alessandro
    Ricci, Dalia
    IMMUNOTHERAPY, 2023, 15 (07) : 471 - 472
  • [32] Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study
    Ueno, Makoto
    Shirakawa, Sachiyo
    Tokumaru, Jumpei
    Ogi, Mizue
    Nishida, Kenichiro
    Hirai, Takehiro
    Shinozaki, Kenta
    Hamada, Yoko
    Kitagawa, Hiroshi
    Horiguchi, Akihiko
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2020,
  • [33] Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study
    Ueno, Makoto
    Shirakawa, Sachiyo
    Tokumaru, Jumpei
    Ogi, Mizue
    Nishida, Kenichiro
    Hirai, Takehiro
    Shinozaki, Kenta
    Hamada, Yoko
    Kitagawa, Hiroshi
    Horiguchi, Akihiko
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2024, 31 (07) : 468 - 480
  • [34] Adjuvant treatment after resection of biliary-tract cancer: yes or no?
    Boucher, Eveline
    Pracht, Marc
    Le Roux, Catherine
    Boudjema, Karim
    Raoul, Jean-Luc
    ONCOLOGY REVIEWS, 2010, 4 (03) : 167 - 170
  • [35] Medical treatment of biliary tract cancer: from peri-operative to palliative care, what's on?
    Boucher, E.
    ONCOLOGIE, 2012, 14 (03) : 150 - 157
  • [36] Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
    Fiteni, Frederic
    Nguyen, Thierry
    Vernerey, Dewi
    Paillard, Marie-Justine
    Kim, Stefano
    Demarchi, Martin
    Fein, Francine
    Borg, Christophe
    Bonnetain, Franck
    Pivot, Xavier
    CANCER MEDICINE, 2014, 3 (06): : 1502 - 1511
  • [37] Current status of chemotherapy for the treatment of advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Koike, Kazuhiko
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2013, 28 (05) : 515 - 524
  • [38] Advances in photodynamic therapy for the treatment of hilar biliary tract cancer
    Kiesslich, Tobias
    Neureiter, Daniel
    Wolkersdorfer, Gernot W.
    Plaetzer, Kristjan
    Berr, Frieder
    FUTURE ONCOLOGY, 2010, 6 (12) : 1925 - 1936
  • [39] Treatment of Borderline Cases for Curative Resection of Biliary Tract Cancer
    Kobayashi, Shogo
    Nagano, Hiroaki
    Marubashi, Shigeru
    Wada, Hiroshi
    Eguchi, Hidetoshi
    Takeda, Yutaka
    Tanemura, Masahiro
    Umeshita, Koji
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (05) : 499 - 503
  • [40] Insulin therapy and biliary tract cancer: insights from real-world data
    Qi, Xiaohui
    He, Ping
    Yao, Huayan
    Sun, Huanhuan
    Qi, Jiying
    Cao, Min
    Cui, Bin
    Ning, Guang
    ENDOCRINE CONNECTIONS, 2022, 11 (03)